Primer: Scribe Therapeutics (SCTX US) - Aug 2026
Scribe Therapeutics is a clinical-stage biotechnology company at the forefront of developing novel CRISPR-based genetic medicines,...
94 Views
Scribe Therapeutics (SCTX): Strong Hands, Strong Start: Scribe Therapeutics Impresses on Debut
​Scribe's successful IPO launch reflects strong institutional demand and strategic investments, with potential for long-term growth despite delayed...
120 Views
Scribe Therapeutics Inc. (SCTX): CRISPR Biotech Attracts Blue-Chip Support, Demand Strong for IPO
​Scribe secures $7.5 million in funding from Sanofi and Eli Lilly for developing CRISPR therapies for cardiovascular markets, with promising Phase...
121 Views
IPO Databook: Scribe Therapeutics (SCTX US) - Jul 2026
Scribe Therapeutics is a clinical-stage biotech company engineering in vivo CRISPR technologies for disease prevention and durable therapeutic...
207 Views
IPO Rating: Scribe Therapeutics, Inc.
Scribe Therapeutics is expected to list on the Nasdaq under the ticker SCTX, offering approximately 7.15 million shares at a price range of $13.00...
245 Views